Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{191310,
        author = {Aditi Abhay Bhagwat and Puja Vyawhare and Dr. Rupali Tasgaonkar},
        title = {In Utero Gene Therapy: A Prenatal Solution to Genetic Diseases},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {12},
        number = {8},
        pages = {6744-6749},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=191310},
        abstract = {In utero gene therapy (IUGT) is a new and promising way to treat genetic diseases before a baby is born; before symptoms even begin. Early treatment is essential for many inherited disorders that begin to compromise the baby’s health during pregnancy or shortly after birth. IUGT uses the special fetal environment which includes immunological tolerance, large populations of stem cells, and developmental flexibility, to provide long-lasting therapeutic effects. This review outlines its potential benefits and limitations, as well as how it functions and which diseases or disorders it may be able to treat. In addition, it discusses about ethical issues and the necessary actions for safely implementing this method in real-world healthcare.},
        keywords = {In utero gene therapy, prenatal treatment, genetic disorders, fetal therapy, early intervention.},
        month = {January},
        }